Matthew Hammond

Matthew Hammond serves as Principal at RA Capital Management, LLC since December 2014 and holds multiple board member positions at Adcytherix, Rampart Bioscience, Jnana Therapeutics, Forge Biologics, Emergence Therapeutics, and DTx Pharma, contributing to significant acquisitions by major companies such as Otsuka, Ajinomoto, Lilly, and Novartis. Previously, Matthew worked as Chief Financial Officer at Research Alliance Corp I from April 2020 to June 2021, leading to a merger with Point Biopharma, later acquired by Lilly. Educational credentials include a Ph.D. in Biomedical Science with a focus on Neuroscience and an M.B.A. in Finance from the University of Connecticut, along with a B.S. in Environmental Health from the University of Georgia.